Craft

Advanced
  • Home
  •  / Vectus Biosystems
Vectus Biosystems

Vectus Biosystems

Stock Price

$0.1

2024-10-14

Market Capitalization

$4.3 M

2024-10-14

Vectus Biosystems Summary

Company Summary

Overview
Vectus Biosystems is a medical research and development company. The company develops treatment for fibrosis and high blood pressure. Its lead compound, VB0004, has potent anti-hypertensive properties as well as anti-fibrotic activity in the heart and kidneys.
Type
Public
Status
Active
Founded
2005
HQ
Rosebery, AU | view all locations
Website
http://www.vectusbiosystems.com.au/
Cybersecurity rating
Sectors

Table of Contents

Key People

  • Karen Duggan, Executive Director and Chief Executive Officer

    • Ronald Shnier, Non-Executive Director

      • Susan Pond, Non-Executive Director

        • Robert Waring, Company Secretary

          LocationsView all

          2 locations detected

          • Rosebery, NSW HQ

            Australia

            3-11 Primrose Ave

          • North Ryde, NSW

            Australia

            level 3/11 Julius Ave

          Vectus Biosystems Financials

          Summary Financials

          Gross profit (H1, 2026)
          $2.0K
          Net income (H1, 2026)
          ($732.0K)
          Cash (H1, 2026)
          $330.0K
          EBIT (H1, 2026)
          ($714.0K)
          Enterprise value
          $4.5M

          Competitors and Similar Companies

          Compare competitors

          Footer menu

          Product

          Solutions

          Resources

          Company

          © Craft.co 2026
          Share price data provided by IEX